Part 6. PET Radiopharmaceuticals

1. What Does PET stand for?:

a.      Positive Effective Therapy

b.      Proton Emission Tomography

c.      Positron Effective Therapy

d.      None of the Above

2. Which ONE of the following isotopes can NOT be used for Coincidence Imaging?

a.          Co-57

b.          C-11

c.          O-15

d.          N-13

3. Which ONE of the following series contains ONLY positron emitters?

a.          Rb-82, F-18,Co-57

b.          N-13, F-18, Co-57

c.          C-11, N-13, Rb-82

d.          I-123, I-125, I-131

            4. Which ONE of the following oncologic indications has NOT been approved by Medicare for reimbursement?

a.      Testicular Carcinoma

b.      Ovarian Cancer

c.      Lymphoma

d.      Colorectal Cancer   

5. What is the method of localization of FDG in malignant tumors?:

a.      Metabolic Trapping

b.      Receptor Binding

c.      Metabolic Interpolation

d.      Glucose Intolerance

6. What is the most commonly used PET Radiopharmaceutical worldwide?

a.F-18 FDG

b.C-11 Labeled CO₂

c..  N-13 Ammonia

d.O-15 H₂O

7. Which Statement is Correct?

a.      FDG is the only F-18 compound ever synthesized for nuclear medicine usage.

b.      F-18 has synthesized several compounds for use in nuclear medicine.

c.      N-13 Ammonia has a better half life than F-18 for clinical nuclear medicine usage.

d.      Rb-82 has never been used for PET imaging.

8. The Half Life of F-18 is?:

a.      118 minutes

b.      18 minutes

c.      110 minutes

d.      2.04 minutes

9. For which of the following conditions does PET have great diagnostic value?:

a.Metastatic Disease

b.Differentiating Necrosis From Tumor

c.Primary Tumors

d.All of the Above

10. Which is a correct statement about PET radiopharmaceuticals?

a.      They must alter the process it is trying to image

b.      They must avoid any metabolic interaction.

c.      They must ensure metabolic changes to the target organ.

d.      They must not alter the process it is trying to image.